Why RenovoRx Stock Is Moving Today
Portfolio Pulse from Ryan Gustafson
RenovoRx, Inc. (NASDAQ:RNXT) shares are trading higher after the company released positive interim data from its Phase 3 TIGeR-PaC study of RenovoGem for pancreatic cancer. The data showed an eight-month median progression-free survival benefit for patients receiving treatment with RenovoGem versus standard-of-care. The company is committed to advancing this therapy as rapidly as possible.
June 29, 2023 | 7:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RenovoRx's stock is trading higher following the release of positive interim data from its Phase 3 study of RenovoGem for pancreatic cancer.
The positive interim data from the Phase 3 study of RenovoGem for pancreatic cancer is a significant development for RenovoRx. This could potentially lead to increased investor confidence in the company's ability to develop effective treatments, thereby driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100